Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•Radiology Business
AI Triage Cuts CT Report Turnaround for Pulmonary Embolism—Daytime Only
FDA-backed study finds AI triage tools reduce radiology CT report turnaround times for pulmonary embolism during peak hours.
•Cardiovascular Business
AI Uses Mammograms to Predict Women’s Cardiovascular Disease Risk
AI algorithms can analyze mammograms to predict cardiovascular disease risk, expanding the utility of breast imaging.
•Health Imaging
Most FDA-Cleared AI Devices Lack Pre-Approval Safety Data, Study Finds
A new study finds fewer than 30% of FDA-cleared AI medical devices reported key safety or adverse event data before approval.